SPONSOR
Tongji Hospital
Total Trials
13
Recruiting
13
Phases
Phase 2, Phase 1, Phase 1, Phase 2, Phase 2, Phase 3, Phase 4
Conditions studied: Colorectal Liver Metastasis (CRLM)Central Nervous System DiseasesCervical CancerNeoadjuvant ChemoimmunotherapyFertility PreservationNeuromyelitis Optica Spectrum DisordersHepotacellular CarcinomaCrohn DiseaseLocally Advanced Cervical CancerConcurrent Chemoradiotherapy
Tongji Hospital is a clinical research sponsor with 13 registered studies on ClinicalTrials.gov, of which 13 are actively recruiting participants. Research covers conditions including Colorectal Liver Metastasis (CRLM), Central Nervous System Diseases, Cervical Cancer, Neoadjuvant Chemoimmunotherapy.
The trial portfolio spans Phase 2, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tongji Hospital
How many clinical trials has Tongji Hospital sponsored?
ClinicalMetric currently tracks 13 clinical trials sponsored by Tongji Hospital, of which 13 are actively recruiting participants. These trials cover conditions including Colorectal Liver Metastasis (CRLM), Central Nervous System Diseases, Cervical Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tongji Hospital research focus on?
Tongji Hospital clinical trials span Colorectal Liver Metastasis (CRLM), Central Nervous System Diseases, Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tongji Hospital clinical trial?
To participate in a Tongji Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tongji Hospital trials with current recruitment status updated daily.
Clinical Trials by Tongji Hospital
NCT06988852 Phase 2
Recruiting
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
Colorectal Liver Metastasis (CRLM)
NCT06467773
Recruiting
TSPO-PET/MRI in Surveillance of Neuroinflammation in the Central Nervous System
Central Nervous System Diseases
NCT06289062 Phase 2
Recruiting
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Cervical Cancer
NCT06620809 Phase 1
Recruiting
The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders
NCT07282184 Phase 1, Phase 2
Recruiting
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Hepotacellular Carcinoma
NCT05321758
Recruiting
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
Crohn Disease
NCT06288373 Phase 2, Phase 3
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Cervical Cancer
NCT06646172
Recruiting
Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy
Median Sternotomy
NCT05303285 Phase 4
Recruiting
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Ankylosing Spondylitis (AS)
NCT07605611
Recruiting
Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection
Rectal Cancer
NCT05961202 Phase 2, Phase 3
Recruiting
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Inflammatory Cardiomyopathy
NCT06529614
Recruiting
An In-situ Detection for MicroRNA
Breast Cancer
NCT07359235 Phase 1
Recruiting
Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)
Bladder Cancer (BC)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology